Renaissance Technologies LLC Purchases 342,300 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Renaissance Technologies LLC grew its position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 33.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,351,640 shares of the company’s stock after purchasing an additional 342,300 shares during the quarter. Renaissance Technologies LLC’s holdings in Xeris Biopharma were worth $3,041,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Xeris Biopharma by 7.3% during the first quarter. Vanguard Group Inc. now owns 7,606,242 shares of the company’s stock worth $16,810,000 after acquiring an additional 519,897 shares during the last quarter. Rosalind Advisors Inc. boosted its position in shares of Xeris Biopharma by 10.6% during the second quarter. Rosalind Advisors Inc. now owns 3,120,170 shares of the company’s stock worth $7,020,000 after acquiring an additional 300,000 shares during the last quarter. Invenomic Capital Management LP boosted its position in shares of Xeris Biopharma by 6.3% during the first quarter. Invenomic Capital Management LP now owns 604,512 shares of the company’s stock worth $1,336,000 after acquiring an additional 35,893 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Xeris Biopharma by 23.0% during the second quarter. Bank of New York Mellon Corp now owns 428,554 shares of the company’s stock worth $964,000 after acquiring an additional 80,015 shares during the last quarter. Finally, NEA Management Company LLC bought a new position in shares of Xeris Biopharma during the first quarter worth $926,000. 42.75% of the stock is currently owned by institutional investors.

Xeris Biopharma Stock Down 0.7 %

XERS stock opened at $2.85 on Tuesday. Xeris Biopharma Holdings, Inc. has a 52 week low of $1.46 and a 52 week high of $3.26. The company has a fifty day simple moving average of $2.66 and a two-hundred day simple moving average of $2.28. The firm has a market capitalization of $424.65 million, a P/E ratio of -6.06 and a beta of 2.76.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.01. Xeris Biopharma had a negative net margin of 32.83% and a negative return on equity of 16,662.63%. The business had revenue of $48.07 million during the quarter, compared to analyst estimates of $46.80 million. During the same quarter last year, the business earned ($0.14) earnings per share. As a group, analysts anticipate that Xeris Biopharma Holdings, Inc. will post -0.4 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Xeris Biopharma in a research report on Thursday, August 15th.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.